-
Evidence-based spiritual assessment tools are presented in this manuscript, which open a dialogue between patients and physicians. These adjunctive therapeutic interventions have been found to improve outcomes for patients with depression, cardiovascular disease, pain, anxiety, and adolescent risk behaviors.
-
In a nursing home-eligible population with a mean age of 80, those with a HbA1c between 8% and 8.9% had less functional decline than those with a HbA1c of 7% to 7.9%.
-
Quality-of-life Effects of PSA Screening; Secondary Prevention of Lacunar Stroke; PSA Elevations After Prostate Cancer Radiotherapy
-
Scenario: The lead II rhythm strip shown above was observed on telemetry. Is the patient in atrial flutter?
-
The FDA has approved an ethyl ester of eicosapentaenoic acid (EPA) to treat hypertriglyceridemia. It is the second drug in this class after Lovaza, which contains esters of both EPA and DHA (docosahexaenoic acid). Icosapent ethyl is marketed by Amarin Pharmaceuticals, a Dublin, Ireland-based company, as Vascepa.
-
Nightly melatonin improved objective and subjective sleep quality in a small number of patients who were taking beta-blockers for hypertension.
-
A modified recombinant human granulocyte colony-stimulating factor (G-CSF) has been approved by the FDA.
-
In a prospectively followed cohort of obese, non-diabetic men and women from Sweden, individuals who underwent bariatric surgery had an 83% reduction in the risk of developing type 2 diabetes over 15 years of follow-up.
-
Three common medications amitripty-line, duloxetine, and pregabalin all appear equally efficacious in treating neuropathic pain from diabetic neuropathy.
-
Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.